GEF-CILAD
Narrowband UVB Phototherapy in Dermatology: GEF-CILAD 2026 Update
Abstract
This document updates the scientific evidence and clinical practice regarding narrowband UVB phototherapy (NB-UVB) in dermatology. The review addresses indications, therapeutic regimens, safety aspects, combinations with systemic and biologic agents, and adaptation to special populations. NB-UVB remains a first-line therapy for psoriasis, vitiligo, atopic dermatitis, early mycosis fungoides, and photodermatoses due to its efficacy, safety, and cost-effectiveness. Emerging evidence supports its integration with next-generation systemic therapies. This update provides recommendations for its application in the era of targeted therapies, with an emphasis on efficiency and patient-centered care.
Source and rights
Published by Actas dermo-sifiliograficas, 2026. The guideline itself is at the source linked here.
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
- Organisation
- GEF-CILAD
- Published
- 2026
- Applies to
- 🇦🇷 Argentina, 🇨🇱 Chile, 🇨🇴 Colombia, 🇪🇸 Spain, 🇺🇾 Uruguay
- Scope
- Regional
- Journal
- Actas dermo-sifiliograficas
- PubMed
- 42323047
More in dermatology
- Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitorsNational Psoriasis Foundation Medical Board and the International Psoriasis Council · 2026
- Generalized Pustular Psoriasis: Review and Consensus of the Psoriasis Group of the Spanish Academy of Dermatology and VenereologySpanish Academy of Dermatology and Venereology · 2026
